Minocycline oral dosage forms for the treatment of acne

Details Minocycline oral dosage forms for the treatment of acne Minocycline oral dosage forms for the treatment of acne

2007-04-02

2009-06-09

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S452000, C424S457000, C424S458000, C424S465000, C424S474000, C424S489000, C424S494000, C424S495000, C424S497000, C424S498000, C514S152000

Reexamination Certificate

active

07544373

ABSTRACT:
Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

REFERENCES:
patent: 3932615 (1976-01-01), Ito et al.
patent: 3957980 (1976-05-01), Noseworthy
patent: 3966922 (1976-06-01), Okamoto et al.
patent: 4086332 (1978-04-01), Armstrong
patent: 4126680 (1978-11-01), Armstrong
patent: 4369172 (1983-01-01), Schor et al.
patent: 4376118 (1983-03-01), Daher et al.
patent: 4443442 (1984-04-01), Skillern
patent: 4701320 (1987-10-01), Hasegawa et al.
patent: 4764377 (1988-08-01), Goodson
patent: 4792448 (1988-12-01), Ranade
patent: 4806529 (1989-02-01), Levy
patent: 4837030 (1989-06-01), Valorose, Jr. et al.
patent: 4925833 (1990-05-01), McNamara et al.
patent: 4935411 (1990-06-01), McNamara et al.
patent: 4935412 (1990-06-01), McNamara et al.
patent: 4960913 (1990-10-01), Szalay et al.
patent: 5007790 (1991-04-01), Shell
patent: 5122519 (1992-06-01), Ritter
patent: 5167964 (1992-12-01), Muhammad et al.
patent: 5188836 (1993-02-01), Muhammad et al.
patent: 5202128 (1993-04-01), Morella et al.
patent: 5209978 (1993-05-01), Kosaka et al.
patent: 5211958 (1993-05-01), Akkerboom et al.
patent: 5217493 (1993-06-01), Raad et al.
patent: 5230895 (1993-07-01), Czarnecki et al.
patent: 5262173 (1993-11-01), Sheth et al.
patent: 5277916 (1994-01-01), Dwyer et al.
patent: 5283065 (1994-02-01), Doyon et al.
patent: 5300304 (1994-04-01), Sjetj al.
patent: 5324751 (1994-06-01), DuRoss
patent: 5348748 (1994-09-01), Sheth et al.
patent: 5413777 (1995-05-01), Sheth et al.
patent: 5459135 (1995-10-01), Golub et al.
patent: 5518730 (1996-05-01), Fuisz
patent: 5554654 (1996-09-01), Yu et al.
patent: 5582837 (1996-12-01), Shell
patent: 5665776 (1997-09-01), Yu et al.
patent: 5674539 (1997-10-01), Tomas
patent: 5776489 (1998-07-01), Preston et al.
patent: 5780049 (1998-07-01), Dickner et al.
patent: 5800836 (1998-09-01), Morella et al.
patent: 5814331 (1998-09-01), Holen
patent: 5834450 (1998-11-01), Su
patent: 5855904 (1999-01-01), Chung et al.
patent: 5908838 (1999-06-01), Gans
patent: 5972389 (1999-10-01), Shell et al.
patent: 6087382 (2000-07-01), Bonner, Jr. et al.
patent: 6120803 (2000-09-01), Wong et al.
patent: 6165513 (2000-12-01), Dansereau et al.
patent: 6165999 (2000-12-01), Vu
patent: 6194000 (2001-02-01), Smith et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 6340476 (2002-01-01), Midha et al.
patent: 6429204 (2002-08-01), Golub et al.
patent: 6455583 (2002-09-01), Pflugfelder et al.
patent: 6497902 (2002-12-01), Ma
patent: 6638922 (2003-10-01), Ashley et al.
patent: 6673843 (2004-01-01), Arbiser
patent: 6863830 (2005-03-01), Purdy et al
patent: 7211267 (2007-05-01), Ashley
patent: 2002/0015731 (2002-02-01), Appel et al.
patent: 2003/0082120 (2003-05-01), Milstein
patent: 2003/0130240 (2003-07-01), Ashley
patent: 2003/0139380 (2003-07-01), Ashley
patent: 2003/0199480 (2003-10-01), Hayes et al.
patent: 2003/0229055 (2003-12-01), Ashley
patent: 2004/0002481 (2004-01-01), Ashley et al.
patent: 2004/0115261 (2004-06-01), Ashley
patent: 2004/0127471 (2004-07-01), Reisberg
patent: 2005/0136107 (2005-06-01), Patel et al.
patent: 2005/0148552 (2005-07-01), Ryan et al.
patent: 2006/0293290 (2006-12-01), Wortzman
patent: 2025703 (1990-09-01), None
patent: 2068366 (1992-11-01), None
patent: 2090561 (1993-02-01), None
patent: 0 184 389 (1986-06-01), None
patent: 0 418 565 (1991-03-01), None
patent: 0 558 913 (1992-09-01), None
patent: 2414668 (2005-12-01), None
patent: 02006437 (1990-01-01), None
patent: WO 93/18755 (1993-09-01), None
patent: WO 98/11879 (1998-03-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 99/58131 (1999-11-01), None
patent: WO 02/080932 (2002-10-01), None
patent: WO 03/088906 (2003-10-01), None
patent: WO 2004/012700 (2004-02-01), None
patent: WO 2004/078111 (2004-09-01), None
MinoPAC product information,Monthly prescribing Reference (Oct. 2006) and the product information (Aug. 2007).
U.S. Appl. No. 11/695,528, filed Apr. 2, 2007, Mitchell Wortman.
U.S. Appl. No. 11/695,513, filed Apr. 2, 2007, Mitchell Wortman.
U.S. Appl. No. 11/695,541, filed Apr. 2, 2007, Mitchell Wortman.
U.S. Appl. No. 11/695,514, filed Apr. 2, 2007, Mitchell Wortman.
U.S. Appl. No. 11/747,866, filed May 11, 2007, Mitchell Wortman.
A Comparison of the Side Effects Produced by Vectrin and Dynacin After Normal Dosage. Clinical Acne Reviews, vol. Oct. 2, 1977.
AAI International PROCORE® Technology.
AAI International PROSLO™ and PROSLO™ II Tablets Technology.
AAI International PROSORB® Technology.
Aditya K. Gupta et al., Solodyn (Minocycline HCI, USP) Extended-Release Tablets, LE JACQ, 291-292, Nov. Dec. 2006.
AJ Darrah et al, An open multicentre study to compare fusidic acid lotion and oral minocycline in the treatment of mild-to-moderate acne vulgaris of the face, European Journal of Clinical Research 8:97-107, 1996.
Allen N. Sapadin et al., Tetracyclines: Nonantibiotic properties and their clinical implications, American Academy of Dermatology, Inc., 258-265, Feb. 2006.
Arndt et al., “What disorders present with inflamed skin?” Cutaneous Medicine and Surgery, An Intergrated Program in Dermatology, vol. 1, pp. 470-471, 1996.
Arnold et al., Andrews' Diseases of the Skin: Clinical Dermatology, 8thEdition, p. 254, 1990.
Bal L. Lokeshwar et al., Inhibition of Cell Proliferation, Invasion, Tumor Growth and Metastasis by an Oral Non-Antimicrobial Tetracycline Analog (COL-3) in a Metastatic Prostate Cancer Model, International Journal of Cancer: 98, 297-309 (2002).
Barbara Fingleton, CMT-3 CollaGenex, Current Opinion in Investigational Drugs, vol. 4, No. 12, 1460-1467, Dec. 2003.
Brigitte Dreno, Multicenter Randomized Comparative Double-Blind Controlled Clinical Trail of the Safety and Efficacy of Zinc Gluconate versus Minocycline Hydrochloride in the Treatment of Inflamatory Acne vulgaris, Dermatology 203:135-140, 2001.
Champion et al., “Disorders of the Sebaceous Glands,” Textbook of Dermatology, 6thEdition, vol. 3, pp. 1958-1961, 1998.
Charles G. Hubbell et al. Efficacy of Minocycline Compared with Tetracycline in Treatment of Acne Vulgaris, Archives of Dermatology, vol. 118. 989-992, Dec. 1982.
E D Millar et al, A general practice study investigating the effect of minocycline (Minocin) 50 mg bd for 12 weeks in the treatment of acne vulgaris, The British Journal of Clinical Practice, vol. 41, 8, 882-886, Aug. 1987.
F. Smit, Minocycline versus Doxycycline in the Treatment of Acne vulgaris, Dermatolgica 157:186-190, 1978.
Falk Ochsendorft, Systemic antibiotic therapy of acne vulgaris, Journal der Deutschen Dermatologischen Gesellschaft, 4:828-841, 2006.
Fleischer, A.B. et al. Safety and Efficacy of a New Extended-Release Formulation of Minocycline. Cutis 2006; 78 (suppl 4):21-31.
Freedberg, et al., Fizpatrick's Dermatology in General Medicine, 5thEdition, vol. 1, pp. 77-778, 1999.
G. F. Webster, Suppression of Polymorphonuclear Leukocyte Chemotactic Factor Production in Propionibacterium acnes by Subminimal Inhibitory Concentrations of Tetracycline, Ampicillin, Minocycline, and Erythromycin, Antimicrobial Angets and Chemotherapy, May 1982, p. 770-772, vol. 21, No. 5.
Garner et al, Minocycline for Acne Vulgaris: Efficacy and Safety, http://212.49.218.203
ewgenMB/ASP/printDocument.asp, Apr. 14, 2004.
Gilbert et al., Extended-Release Minocycline: Is Efficacy Dose- dependent in the Approved Dose Range?, Poster Presentation for the DUSA Pharmaceuticals, Inc. Medical Conferences and Trade Shows, Hawaii, Mar. 3-9, 2007.
Guy F. Webster, Inflammation in acne vulgaris, Clinical Reviews, Journal of the American Academy of Dermatology vol. 33, No. 2, Part 1, 248-253, Aug. 1995.
H. Akamatsu et al., Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism, Archives of Dermatological Research, 1991, 283: 524-528.
Hirohiko Akamatsu et al., Effect of Doxycycline on the Generation of Reactive Oxygen Species, Acta Derm Venereol (Stockholm), 1992; 72: 179-179.
Is minocycline overused in acne?, Dru

Affiliated with

Also associated with

Rating

Minocycline oral dosage forms for the treatment of acne does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Minocycline oral dosage forms for the treatment of acne, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Minocycline oral dosage forms for the treatment of acne will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4080573